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Replacing the First Epidermal Growth Factor-like Domain of Factor IX with That of 
Factor VII Enhances Activity In Vitro and in Canine Hemophilia B
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Using the techniques of molecular biology, we made a chi-
meric Factor IX by replacing the first epidermal growth fac-
tor–like domain with that of Factor VII. The resulting re-




, had at least
a twofold increase in functional activity in the one-stage
clotting assay when compared to recombinant wild-type
Factor IX. The increased activity was not due to contamina-
tion with activated Factor IX, nor was it due to an increased
rate of activation by Factor VIIa-tissue factor or by Factor
XIa. Rather, the increased activity was due to a higher af-











tor VIIIa about one order of magnitude lower than that of
recombinant wild-type Factor IXa. In addition, results from
animal studies show that this chimeric Factor IX, when in-
fused into a dog with hemophilia B, exhibits a greater than
threefold increase in clotting activity, and has a biological



























Coagulation Factor IX is a single-chain serine protease zy-
mogen that can be activated to a two-chain serine protease
(Factor IXa) by release of an activation peptide (1). The cata-
lytic domain of Factor IXa is located in the heavy chain. The








-carboxyglutamic acid) domain, the aro-
matic stack, and the two EGF-like domains.
In the coagulation cascade, Factor IXa activates Factor X
to Factor Xa, leading to thrombin generation. To activate





cofactor, Factor VIIIa, for optimal activity (2–4). Factor VIIIa
is a calcium-dependent heterotrimer that consists of two A do-
mains (A1, A2), a third A domain (A3), and two C domains
linked by a calcium bridge. Factor VIII circulates as an inac-
tive cofactor (tightly bound to von Willebrand factor), and
is activated by serine proteases like thrombin (5, 6) or Factor
Xa (7).
Recombinant DNA techniques have led to the production
of several chimeric Factor IX molecules (8–12). A chimeric
Factor IX molecule containing the EGF-1 domain of Factor X
or protein C was reported to have near normal or reduced in
vitro clotting activity, respectively (8, 11). Here we report an-
other observation, namely a chimeric Factor IX molecule con-
taining the EGF-1 domain from Factor VII, that possesses in-
creased clotting activity both in vitro and in vivo. The
enhanced activity is due to an increased affinity of the chimeric
Factor IX for Factor VIIIa, suggesting that the EGF-1–like do-






Plasma Factor XIa was purchased from Enzyme Research
Laboratories (South Bend, IN). Factor VIII was purified from Profi-
late (Alpha Therapeutic Corp., Los Angeles, CA) by gel filtration on
Sepharose CL2B. Thrombin and antithrombin III were purified as
previously described (13, 14). Factor VIII-, IX-, and X-deficient plas-
mas were obtained from HRF, Inc. (Raleigh, NC). Kontact aPTT re-











 102,000) was purchased from Sigma
Chemical Co., (St. Louis, MO). Phosphatidylcholine (1-palmitoyl-
2-oleoyl lecithin) and phosphatidylserine (disodium salt) were ob-
tained from Avanti Polar Lipids (Alabaster, AL). Hirudin was pur-










-nitroanilide acetate) was purchased from American Diagnos-
tica, Inc. (Greenwich, CT). The monoclonal antibody, AHIX-5041,
that recognizes human Factor IX heavy chain, was obtained from
Haematologic Technologies, Inc. (Essex Junction, VT). Rabbit anti–
human Factor IX antibody was purchased from Dako Corp. (Carpin-
teria, CA). Biotin-coupled goat anti–rabbit antibody was purchased
from Vector Laboratories, Inc. (Burlingame, CA).
 
Chimeric DNA construction, expression, and purification of the re-
combinant proteins.
 
The chimeric and wild-type Factor IX DNA
construct, protein expression, purification, and characterizations
were as described previously (12). In brief, both normal Factor IX
cDNA and chimeric Factor IX cDNA were cloned respectively into
an expression vector pCMV5 (15) and transfected into a human kid-
ney cell line 293 (ATCC CRL 1573) together with pSV2neo by the
calcium phosphate coprecipitation method (16). The recombinant
protein was expressed in serum-free media and purified by a pseudo-
affinity chromatographic method using Fast Flow Q-Sepharose and




Large unilamellar phospholipid vesicles
containing a 30/70 molar ratio of phosphatidylserine to phosphatidyl-
choline were prepared by extrusion using a previously described pro-




C under argon (19).
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The active site concentration of each acti-
vated Factor IX was determined as previously described by titration




The one-stage clotting assay for Factor IX was
performed according to the method previously described (21). In
brief, a standard curve was constructed by performing partial throm-
boplastin times on serial dilutions of normal human plasma into hu-
man hemophilic B plasma. The clotting times of similar dilutions of
test plasmas were compared to the standard curve, which was defined
as 100%.
 
Activation of Factor IX.
 
Activation of Factor IX by Factor XIa or
Factor VIIa-tissue factor complex was performed as described by
Zhong et al. (11).
 
Binding of Factor IXa to Factor VIIIa.
 
To determine the affinity
of both normal Factor IXa and chimeric Factor IXa for Factor VIIIa,




l reaction, the con-
centrations of each component were: 0.2 nM Factor VIII; 200 nM








M phospholipid; 0.5 mM Spectrozyme
fXa; and Factor IXa ranging from 0.02 to 4 nM. Factor VIII was incu-
bated with thrombin at room temperature for 5 min. Hirudin in molar
excess over thrombin and phospholipid was then added to the reac-




l of the Factor VIIIa,
thrombin, hirudin, and phospholipid solution was aliquoted to a mi-




l of Factor IXa at various concentra-




, and Spectrozyme fXa were then added to each





bance change at 405 nm was monitored. The data were fitted to a sec-












. The a2 coefficient gives the
rate of change in the A405, and is equal to kSpec*kX*[IXa/VIIIa]/2
where kSpec is the rate that Factor Xa cleaves Spectrozyme fXa. The
Factor Xa generation rate was plotted against the concentration of
Factor IXa, and the affinity of Factor IXa for Factor VIIIa was deter-
mined by fitting the data to the equation:
where [FIXa/VIIIa] is determined as described in Larson et al. (22) in
equations 4–10 in a minor modification of the equations reported by
Krishnaswamy (23).
 




 inhibition of in-
trinsic Xase activity.
 
Both wild-type Factor IXa and chimeric Factor
IXa were inhibited by incubating Factor IXa with dansyl Glu-Gly-
Arg chloromethyl ketone (DEGR-CK) for 4 h. Free DEGR-CK was
removed from the proteins by exhaustive dialysis. Both inhibited
forms were used to show that DEGR-chimeric IXa was more effec-
tive than wild-type DEGR-IXa in inhibiting intrinsic Xase activity
(Factor IXa/Factor VIIIa activity). Final concentrations of each com-
ponent were as follows: 0.05 nM Factor VIIIa, 1 nM Factor IXa, 200








M phospholipid, 0.5 mM Spectro-
zyme fXa, and DEGR-Factor IXa ranging from 0.01–20 nM. Factor
VIII was activated as described above, and was added to a mixture of
Factor IXa and DEGR-IXa. Factor X was added, and kinetic mea-
surements were made as described above. Factor Xa generation was







tor VIIIa determined by fitting the data to the equation:
This equation assumes that the concentration of the complex of Fac-
tor IXa with Factor VIIIa is small relative to the concentration of






K i* Kd IXa[ ]+( )
K i*Kd K i* IXa[ ] Kd* DEGR-IXa[ ]+ +
--------------------------------------------------------------------------------------------------=
 
IXa with Factor VIIIa is small relative to the concentration of
DEGR-IXa.
 















 of the Factor IXa/Factor VIIIa com-
plex for Factor X were determined by measuring the Factor Xa gen-
eration in the reaction that contained 0.2 nM Factor VIII, 0.1 nM Fac-








; 0.5 mM Spectrozyme fXa,
and Factor X ranging from 1–400 nM. The assay was performed as
follows: Factor VIII was incubated with thrombin at room tempera-
ture for 5 min before adding hirudin, phospholipid, Factor IXa, and




l of this solution was aliquoted to a microtiter
well, and then Factor X at various concentrations was added to each
well. The changes in 405 nm were monitored and converted to the Xa
generation rate as described above. To monitor Factor Xa generation
in the absence of Factor VIIIa, Factor VIIIa was omitted from the re-













 were determined by fitting data for the Factor Xa




The hemophilia B dog came from the inbred col-
ony maintained since 1966 at the Francis Owen Blood Research Lab-
oratory at the University of North Carolina in Chapel Hill. The ani-
mal studies were performed in accordance with the institutional
guidelines at the University of North Carolina. A hemophilia B dog




 at a dose of 0.08 mg/kg.
Blood samples were taken at 5, 15, and 30 min, and at 1, 2, 4, 8, 12, 22,
24, 46, 48, 70, and 72 h after injection. Recombinant wild-type (nor-
mal) Factor IX (0.08 mg/kg) was also infused into this dog 72 h after
infusion of the chimeric Factor IX. Samples were taken from this dog




. This time was adopted
based on our previous experience in evaluating the functional activity
and biological half-life of human Factor IX preparations in canine he-
mophilia B animal models. As we have previously shown on numer-
ous occasions, no measurable canine antibodies against human Factor
IX could be detected in the dog during the time period of the experi-
ments using human Factor IX. Whole blood clotting time was mea-
sured at 15 min, and 4, 8, 24, and 48 h after each injection. ELISA and
the one-stage clotting assay were used to determine the Factor IX an-




Factor IX concentration and characterization.
 
Expression, pu-
rification, and characterization of recombinant proteins were
as described in our previous publication (12). The chimeric
and wild-type Factor IX had 8.8 and 11.1 Gla residues per mol-
ecule, respectively. Neither the wild-type nor the chimeric Fac-
tor IX bound to tissue factor, even though the EGF1 domain
of Factor VII has been shown to be in direct contact with tis-
sue factor (24). Protein concentrations were determined by the








 13.3) and by Bradford assay.




 and wild-type Factor IX
were equivalent as determined by using human plasma Factor
IX as a standard. The protein concentrations were determined
on at least ten different occasions. After full activation, the an-
tithrombin III–titrated active site concentration for wild-type




 revealed that both concentra-
tions were identical.
 
In vitro clotting activities.
 
The in vitro coagulation activi-




 as compared to wild-type
recombinant Factor IX molecules are listed in Fig. 1. The aver-
age activity of wild-type Factor IX zymogen was 92% of nor-








Abbreviations used in this paper:
 
 DEGR-IXa, dansyl Glu-Gly-







value is comparable to that obtained by others (8, 11). Interest-
ingly, an equal concentration of the zymogen chimeric Factor
IX had more than twofold higher activity than wild-type Fac-
tor IX. To show that the increased activity was not due to small
amounts of activated Factor IX in the zymogen preparation,
both the chimeric and wild-type preparations were fully acti-
vated by the addition of Factor XIa and calcium. Even when
fully activated, chimeric Factor IXa still has twice the activity
of the wild-type Factor IXa (Fig. 1). These data demonstrate
that on a mole for mole basis, chimeric Factor IX had twice the











To determine the mechanism responsible for the increased









) increased rate of activa-














) increased catalytic activity toward




Fig. 2 shows the activation pattern
of both chimeric and wild-type Factor IX by Factor XIa. As
can be seen on reduced SDS-PAGE, activation of chimeric and
wild-type Factor IX occur at essentially the same rate, both be-
ing completely activated by 30 min under these conditions.
These data suggest that the increased activity of the chimera is
not due to an increased rate of activation by Factor XIa.
 
Factor VIIa-tissue factor activation.
 
SDS-PAGE analysis of
the activation of chimeric and wild-type Factor IX by Factor
VIIa/tissue factor is shown in Fig. 3. The results indicate that
the activation pattern of chimeric and wild-type Factor IX is
essentially identical. From these data, it does not appear that
differences in the rate of activation by Factor VIIa/tissue fac-
tor account for the differences in activity between wild-type
and chimeric Factor IXa.
 
Factor Xa generation in the absence of Factor VIIIa.
 
In a
Factor Xa generation assay in which Factor VIIIa was omitted,
the amount of Factor Xa generated by chimeric and wild-type






 of 147 nM with re-
spect to Factor X for wild-type, and 149 nM for chimeric Fac-
tor IXa; data not shown). These data indicate that the in-
creased activity of the chimera was not due to direct activation
of Factor X independent of Factor VIIIa.
 
Factor IXa interaction with Factor VIIIa.
 
The binding affin-
ity of activated Factor IX for Factor VIIIa was determined as
described in Methods. When the assay was controlled so that
the concentrations of Factor VIIIa, phospholipid vesicles, Fac-
tor X, and calcium ions were constant, and the concentration
of Factor IXa was varied, Factor Xa generation would reflect
the interaction between Factor IXa and Factor VIIIa. The
lower the concentration of Factor IXa required for Factor Xa
generation to reach saturation, the tighter the binding of Fac-





–Factor VIIIa complex activates more Factor X at
Figure 1. Clotting activity of recombinant Factor IX. 
The domain structure of both Factor IX and Factor 
IXVIIEGF1 are shown. The filled region with white letter-
ing indicates that the domain has the sequence of Fac-
tor VII. Clotting activity for both the zymogen and 
activated forms was determined as described in Meth-
ods, and reported as a percent of the values seen for 
wild-type.
Figure 2. Activation of Factor IX by Factor XIa. Either normal Fac-
tor IX (A) or Factor IXVIIEGF1 (B) was incubated with Factor XIa and 
calcium. At timed intervals, samples were removed for reduced SDS-
PAGE on 10–27% acrylamide gels. Samples were visualized by Coo-
massie staining. Lanes 1–9 show time points at 0, 1, 2, 4, 8, 12, 16, 30, 
and 60 min, respectively.
Figure 3. Activation of Factor IX by Factor VIIa/tissue factor. Either 
normal Factor IX (A) or Factor IXVIIEGF1 (B) was incubated with tis-
sue factor/Factor VIIa and calcium. At timed intervals, samples were 
removed for reduced SDS-PAGE on 10–27% acrylamide gels. Sam-
ples were visualized by Coomassie staining. Lanes 1–9 show time 
points at 0, 1, 2, 4, 8, 12, 16, 30, and 60 min, respectively.
 




lower concentrations of Factor IXa than does wild-type Factor





. The data were calculated according to the report of
Krishnaswamy (23), and Larson et al. (22) to obtain the kinetic














wild-type, indicating that the chimeric molecule has a higher
affinity for Factor VIIIa than does the wild-type. Fig. 5 shows
Factor X activation by both wild-type Factor IXa–Factor VIIIa
and chimeric Factor IXa–Factor VIIIa. These data were nor-
malized for the amount of Xase complex using the constants
determined in Fig. 4 and shown in Table I. As can be seen,
both chimeric Factor IXa and wild-type Factor IXa activate
Factor X at similar rates (Table I). These data indicate that the
primary difference between chimeric and wild-type Factor IXa
is in their affinity for Factor VIIIa.
To confirm that chimeric Factor IXa has a higher affinity for
Factor VIIIa than wild-type Factor IXa, we used DEGR-
Figure 4. Factor IXa binding to Factor VIIIa. The rate of Factor X 
activation as a function of varied concentrations of normal Factor IX 
(open triangles) or Factor IXVIIEGF1 (closed circles) with fixed concen-
trations of Factor VIIIa, phospholipid, and Factor X was assayed as 
described in Methods. Binding of Factor IXa to Factor VIIIa (Kd) 
was determined by fitting the data to the equations described in Lar-
son et al. (22).
 
Table I. Factor Xa Generation by Chimeric and Wild-type 

































































*The affinity of Factor IXa for Factor VIIIa; ‡maximum Factor Xa gen-
eration at saturation of Factor VIIIa with Factor IXa; §the affinity of
the Factor IXa/Factor VIIIa complex for Factor X; ‡rate constant for
activation when Factor X is saturating. Raw data in the experiment are
corrected for the amount of Factor IXa-Factor VIIIa complex.
Figure 5. Factor IXa/VIIIa interaction with Factor X. The rate of 
Factor X activation with constant Factor IXa, Factor VIIIa, and phos-
pholipid and varied Factor X concentrations was determined as de-
scribed in Methods. Open triangles show the data for normal Factor 
IXa, and closed circles show the data for Factor IXaVIIEGF1. The data 
is expressed as moles of Factor Xa per min per mole of the Factor 
IXa/VIIIa complex. The amount of Xase complex (which is different 
for chimeric and wild-type Factor IXa) was determined using the Kd 
values determined in Fig. 4 and shown in Table I using the equations 
described by Krishnaswamy (23) and Larson et al (22). The kinetic 
constants (Km and kcat) were calculated using the equation shown in 
Methods.
Figure 6. DEGR-IXa inhibition of intrinsic Xase activity. The ability 
of varied concentrations of DEGR-IXa to inihibit Factor X activation 
by Factor IXa, Factor VIIIa, and phospholipid was measured as de-
scribed in Methods. The rate of Factor X activation in the presence of 
DEGR-IXa was normalized relative to rate seen in the absence of 
DEGR-IXa. Open triangles show the data for normal Factor IXa, and 
closed circles show the data for Factor IXaVIIEGF1. Binding of DEGR-
IXa to Factor VIIIa (Ki) was determined using the equation shown in 
Methods.
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CK–inhibited Factor IXa to show that DEGR chimeric Factor
IXa was more effective than DEGR wild-type Factor IXa in
inhibiting Factor IXa/Factor VIIIa interaction. These data are
shown in Fig. 6. The Xase activity of either wild-type Factor
IXa/Factor VIIIa (Fig. 6) or chimeric Factor IXa/Factor VIIIa
(data not shown) is more effectively inhibited by DEGR chi-
meric Factor IXa than by DEGR wild-type Factor IXa. As
shown in Table II, the Ki for Factor VIIIa is five to sixfold
higher for DEGR wild-type Factor IXa than for DEGR chi-
meric Factor IXa. These data indicate that DEGR chimeric
Factor IXa has a higher affinity for Factor VIIIa than does
wild-type Factor IXa.
Animal studies. The animal studies were conducted (a) to
confirm that increased clotting activity is not due to contami-
nation of the zymogen with activated Factor IX since Factor
IXa is rapidly cleared in vivo; (b) to determine if Factor
IXVIIEGF1 functions well in vivo; and (c) to investigate the po-
tential of this chimeric Factor IX for future therapeutic use.
Equal amounts of chimeric and wild-type Factor IX were in-
fused into a hemophilia B dog as described in Methods (0.08
mg/kg). The dog exhibited no redness or swelling at the site of
injection, and showed no evidence of thrombotic complica-
tions with either infusion. Results from this experiment dem-
onstrated that the clearance of Factor IX antigen and activity
were similar for both chimeric and wild-type molecules (Fig.
7). The whole blood clotting time was shortened from longer
than 40 min to a normal value of , 10 min with each infusion,
suggesting that both the chimeric and wild-type proteins func-
tion well in vivo. As can be seen in Fig. 7 A, the amount of chi-
meric Factor IX recovered was less than the wild-type Factor
IX as measured by an ELISA based on a monoclonal capture
antibody that recognized the heavy chain of Factor IX and a
rabbit anti–human Factor IX–detecting antibody. In control
experiments, the ELISA reading for chimeric Factor IX was
z 10% less than for wild-type Factor IX (as expected). The re-
covered antigen level of the chimeric Factor IX, however, was
23–65% lower than the wild-type at the same time points. This
data suggests that factors other than differences in the ELISA
account for the lower recovery. Even given a lower recovery,
the chimeric Factor IX had up to fourfold higher activity than
did wild-type Factor IX with an average increase in activity
that was 2–3 times higher than wild-type Factor IX (Fig. 7 B).
Discussion
Our initial observation showed that Factor IXVIIEGF1 had at
least twofold higher clotting activity than normal Factor IX. Two
obvious explanations could account for this observation: (a) a
discrepancy in the amount of protein used in the assay, or (b)
chimeric Factor IX contaminated with small amounts of Fac-
tor IXa. Careful protein measurements were repeated in more
than ten separate experiments using absorbance at 280 nm
(e1% 5 13.3) as well as the Bradford method to confirm the
protein concentration. In addition, both chimeric and normal
Factor IX were fully activated by the addition of Factor XIa
and calcium. Even after full activation, the chimera still re-
tained about twofold higher clotting activity than did the wild-
type protein, indicating that the higher activity was not due to
contamination with activated Factor IX. In experiments not
shown, the active site of both proteins was titrated using anti-
thrombin III, which showed that the same number of active
sites were present in both protein preparations.
Other possible mechanisms to explain increased activity in
the chimeric molecule include: (a) increased activation rate by
Factor XIa; (b) increased activation rate by Factor VIIa-tissue
factor (although in theory there is no tissue factor present in a
Table II. Inhibition of Factor Xa Generation by Factor
IXa/VIIIa Using DEGR–Chimeric Factor IXa and





Ki (nM) Ki (nM)
Wild-type Factor IXa 0.3660.05 0.06560.008
Chimeric Factor IXa 0.1660.01 0.03860.002
Figure 7. Factor IX activity and antigen levels from a hemophilia B 
dog. Factor IX antigen levels in the dogs (A) were determined by 
ELISA. Factor IX activity levels in canine plasma (B) were deter-
mined by clotting assays, and were compared to a standard curve as 
described in Methods. Open triangles show the data for normal Fac-
tor IX. Closed circles show the data for Factor IXVIIEGF1.
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one-stage clotting assay); (c) enhanced activation of Factor X
in the absence of Factor VIIIa; (d) increased catalytic activity
toward Factor X; or (e) increased affinity for Factor VIIIa. As
shown in results, both Factor IXVIIEGF1 and normal Factor IX
were activated similarly by Factor XIa and Factor VIIa tissue
factor (Figs. 1 and 2). These experiments show that neither ac-
tivation pathway contributes to the higher activity of the chi-
meric protein. The possibility that replacing the EGF1 domain
of Factor IX with that of Factor VII would alter the function of
the chimeric protein so as to bypass the requirement for Factor
VIIIa was excluded since both wild-type and chimeric Factor
IXa had the same activity in a system containing Factor IXa,
phospholipid, and calcium, but in the absence of Factor VIIIa.
To exclude the possibility that chimeric Factor IXa had in-
creased catalytic activity toward Factor X in the presence of
Factor VIIIa, we showed that the Km and kcat of both activated
proteins toward Factor X were essentially similar (Fig. 5 and
Table I). These data indicate that the turnover of Factor X re-
flecting increased catalytic activity does not explain the in-
creased activity of the chimeric molecule. On the other hand,
our data shows that the Kd of the activated chimera for Factor
VIIIa is 10-fold lower than that for wild-type Factor IX
while the Vmax for Factor Xa generation remains the same.
The lower Kd of the chimera indicates that Factor IXVIIEGF1 has
a higher affinity for Factor VIIIa than for the normal pro-
tein. This conclusion is supported by the experiments using
DEGR-CK–inhibited Factor IXa. The DEGR chimeric Factor
IXa is five to sixfold more potent than DEGR wild-type Fac-
tor IXa, as measured by inhibition of intrinsic Xase activity.
Many investigators have tried to pinpoint the functional
role of each domain in Factor IX. Some have suggested that
the EGF1 domain of Factor IX is involved in binding to Factor
VIIIa (25). Others have suggested that the same domain is re-
quired for Factor VIIa-tissue factor activation of Factor IX,
and for Factor IXa interaction with Factor X (11). Zhong et al.
(11) reported that when the first EGF domain of Factor IX
was substituted with the same domain of protein C, that, in
contrast to the results with Factor IXVIIEGF1, activity was mark-
edly reduced. One possible reason for the low activity of the
protein C chimera is the poor sequence homology between the
EGF1 of Factor IX and protein C as shown in Fig. 8. As can be
seen, the EGF1 domain of protein C has nine more residues
and one more disulfide linkage than that of Factor IX. Replac-
ing the EGF1 domain of Factor IX with that of protein C
might simply interrupt the optimal conformation of the chi-
mera and result in a loss of function. A chimeric Factor IX
with the EGF1 domain replaced by that of Factor X was re-
ported to maintain a near normal clotting activity (8). Fig. 8
shows that the EGF1 domains of Factors IX, VII, and X share
the same number of residues, and exhibit a high sequence ho-
mology. Thus, the overall structure of the chimera factor
IXXEGF1 may be preserved by the domain exchange so that its
activity is also preserved. A recent report for the crystal struc-
ture of porcine Factor IXa suggests several residues in the
EGF1 domain (Ile-66, Tyr-69, and Trp-72) may be involved in
contact with Factor VIIIa (26). The related residues are highly
conserved in both Factor X and Factor VII (Leu-66, Tyr-69,
and Trp-72 in Factor X, and Leu-65, Tyr-68, and Phe-71 in
Factor VII). Therefore, replacing the EGF1 domain of Factor
IX with that of Factor VII or Factor X would not necessarily
be expected to lower the clotting activity.
Changing the EGF1 domain of Factor IX to Factor VII al-
tered 12 residues between Cys51 and Cys82. The position of
these residues was mapped onto a crystal structure of porcine
Factor IX using the coordinates deposited in the Brookhaven
data bank by Dr. Brandstetter and colleges (26). EGF1 resi-
dues in the porcine structure that differed from human were
mutated to the appropriate residue using the program Insight
II (Molecular Simulations Incorporated, San Diego, CA).
EGF1 residues were also mutated to the appropriate residue
in Factor VII. Comparing these two models revealed that all
of the residues that were changed were significantly surface-
exposed. A number of the changes were very conservative
(Asn54 to Ser, Ile66 to Leu, Lys80 to Arg), and seem un-
likely to account for the increased activity of the chimeric
protein. One significant change, however, is in the sequence
Pro74-Phe75 in Factor IX that is replaced with Leu-Pro in Fac-
tor IXVIIEGF1. In the model of human Factor IX EGF1, Phe 75
inserts into EGF2 between the parallel sheets that include resi-
dues 94-96 and 121-123. This modeled insertion of Phe75 into
the EGF2 domain (which is only a model since in the porcine
crystal structure the corresponding residue is a valine) may
have two effects on the overall structure. One effect is that
Phe75 creates a pocket in the EGF2 domain that may anchor
EGF2 in a particular orientation relative to EGF1. The other
effect is that Phe75 might distort the backbone structure of
Arg94. Arg94 in the porcine crystal structure forms a salt
bridge with Asp78 of the EGF1 domain, and may serve to ori-
ent EGF1 relative to EGF2. It may be that replacing the EGF1
of Factor IX with that of Factor VII in which Phe75 is replaced
by Pro removes a constraint on the relative orientation of
EGF1 and EGF2, and confers flexibility on the chimeric mole-
cule such that it can achieve a conformation that allows it to in-
teract effectively with Factor VIIIa.
A 10-fold lower Kd allows the same amount of enzyme–
cofactor to be complexed for the chimeric Factor IXa–factor
VIIIa at a lower concentration than normal Factor IXa–Factor
VIIIa. Since the Vmax for both Factor IXa–Factor VIIIa com-
Figure 8. Sequences of the EGF1 
domain of human Factor IX, VII, X, 
and protein C. These sequences are 
arranged so that the first cysteine 
residues are aligned. Cysteine resi-
dues are shown in boxes with light 
shading. Identical residues are 
shown in boxes with darker shading. 
Factor IX and X sequences start at 
residue 47, while Factor VII and protein C sequences start at residue 46. The numbers associated with cysteine residues show the disulfide bond-
ing pattern. Residue 75 in Factor IX is indicated by ‡ and is changed from Phe to Pro in Factor VII. As discussed in the text, changing this residue 
may be significant for orientation of EGF1 relative to EGF2.
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plexes to activate Factor X are the same, once the cofactor,
Factor VIIIa, was saturated, the Factor Xa generation rate be-
comes the same. This suggests that Factor IXVIIEGF1 would
function significantly better at a lower concentration. There-
fore, we performed the animal studies at a dose (0.08 mg/kg)
lower than that commonly used (0.16 mg/kg [27]). Surprisingly,
after infusion into a hemophilia B dog, the measured antigen
level of the chimeric Factor IX was lower than that of normal
Factor IX at each related time point. This suggests that the in
vivo compartmentalization of the two proteins may not be the
same. Since the higher activity of Factor IXVIIEGF1 is caused by
a higher affinity for Factor VIIIa, the practical increase in ac-
tivity would depend on the available amount of the activated
proteins (Factor IXa and Factor VIIIa). In our animal studies,
the assayed activity for Factor IXVIIEGF1 was 200–400% greater
than that of normal Factor IX at each related time point. If one
takes the lower antigen level of the chimera into account and
normalizes it, the specific activity for the chimera would be
. 300% of its counterpart.
It has been shown that chimeric plasma proteins may func-
tion better than their parent molecules (28–30). The reasons
for the increased activity can include reduced plasma clearance
(28, 29) or enhanced structural stability of the whole molecule
(30). Our studies provide for another mechanism since we
show that the increased activity of Factor IXVIIEGF1 is caused
by an enhanced interaction with cofactor. This better interac-
tion gives Factor IXVIIEGF1 increased activity in in vitro assays
as well as in vivo in a hemophilia B dog model. Results from
these experiments show that the disappearance of Factor IX
antigen and activity are similar for the chimeric and normal
molecules in a dog, suggesting they have comparable biologi-
cal half-lives. In addition, no thrombotic complications were
observed, although this is admittedly a short-term test. This
suggests that the Factor IXVIIEGF1 is not only a promising thera-
peutic agent for conventional intravenous therapy of hemo-
philia B, but also a potential promising construct for gene re-
placement therapy of hemophilia B.
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